Interim report
Page 1
October 28, 2026 The Department of Corporate Services- Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789 The Department of Corporate Services- Listing National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM Subject: Outcome of Board Meeting held on October 28, 2026 along with Unaudited Financial Results(Standalone & Consolidated) for the quarter and half year ended September 30, 2026 Dear Sir/ Madam, Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026. In this regard, kindly find enclosed the Unaudited Financial Results (Standalone & Consolidated) along with its Limited Review Report issued by the Statutory Auditors of the Company for the quarter and half year ended September 30, 2026. The Board Meeting commenced at 04:30 p.m. and concluded at 04:56 p.m. We request you to take the above on record. Thanking you, For Jagsonpal Pharmaceuticals Limited Pratham Rawal Company Secretary & Compliance officer Encl: A/a lJAGSONPAL! Jagsonpal Pharmaceuticals Ltd Corporate Office: Plot l\b. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram -122015, Haryana (India) Ph.: +91124 4406710; E-mail: info@jagsonpal.com; Website: www.jagsonpal.com CIN. : L74899DL1978PLC009181 --( ::.:&.mu • -~ Sakht A CSR Initiative Regd. Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 (India) Mumbai Office: 13-14, Unit 3B, Phoenix Paragon Plaza, Kurla West, Mumbai, Maharashtra- 400070
Page 2
Walker Chandiok &_Co LLP Walker Chandiok & Co LLP 21 st Floor, DLF Square Jacaranda Marg, DLF Phase II Gurugram - 122 002 India T +91 124 4628099 F+911244628001 Independent Auditor's Review Report on the Quarterly and Year to date Unaudited Standalone Financial Results of Jagsonpal Pharmaceuticals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Jagsonpal Pharmaceuticals Limited 1. We have reviewed the accompanying statement of unaudited standalone financial results of Jagsonpal Pharmaceuticals Limited ('the Company') for the quarter ended 30 September 2026 and year to date for the period 01 April 2026 to 30 September 2026 (the Statement), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). 2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 {'the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Chartered Accountants Offices in Bengaluru, Chandigarh, Chennal, Gurugram, Hyderabad, Kechi, Kolkata, Mumbai, New Delhi, Naida and Pune Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L-41 Connaught Circus, New Delhi, 110001, India
Page 3
Walker Chandiok &..Co LLP Independent Auditor's Review Report on the Quarterly and Year to date Unaudited Standalone Financial Results of Jagsonpal Pharmaceuticals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd) 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. • For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/ N500013 w Vinod Gupta Partner Membership No. 503690 UDIN: 26503690NBJBBJ1737 Place: Gurugram Date: 28 October 2026
Page 4
Jagsonpal Pharmaceuticals Limited Registered office: lnnov8 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi, 110020 Corporate office: Plot No. 412-415,3rd Floor, Nimai Tower, Phase-IV, Udyog Vihar, Sector 18, Gurugram, Haryana-122015 CIN No:- L74899DL1978PLC009181 Phone:0124-4406710 Statement of Unaudited Standalone Financial Results for the Quarter and Half Year ended 30 September 2026 (Rs. In Million) Quarter ended Half year ended Year ended Sr. No. Particulars 30 September 30 June 30 September 30 September 30 September 31 March 1 2 INCOME Revenue from operations Other Income 2026 2026 2025 2026 2025 2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 813.75 22.31 822.32 28.33 744.65 30.27 1,636.07 50.64 1,500.77 58.52 2,872.25 119.95 3 Total Income (1+2} 836.06 850.65 774.92 1,686.71 1,559.29 2,9~2 20 4 EXPENSES a) Cost of materials consumed b) Purchases of stock-in-trade c) Changes In inventories of finished goods, stock-in-trade and work-in-progress d) Employee benefits expense e) Finance costs f) Depreciation and amortisation expenses g) Other expenses 10 Other comprehensive Income (OCI) I) a) Items that will not be reclassified to profit or loss b) Income tax relating to items that will not be reclassified to profit or loss 11 Total comprehensive income for the period/year (9+10) 12 Earnings per share (not annualised for the quarters/periods) Basic lin Rs.) Diluted (In Rs.) 13 Paid-up equity share capital (face value per share Rs. 2) 14 Reserves excluding revaluation reserves (other equity) See accompanying notes to the unaudited standalone financial results 46.78 48.66 252.99 260.50 17,90) (22.92) 220.05 227.78 2.51 2.51 16.83 21.42 134.17 135.90 (2.71) 1.26 0.69 10.32) 123.88 132.83 1.91 2.00 1.87 1.98 133.27 131.68 SIGNED FOR IDENTIFICATION PURPOSES 38.43 95.44 91.75 161.13 237.98 513.49 464.87 891.88 14,13) (30.82) (15.07) (9.26) 181.75 447.83 376.16 707.40 2.65 5.02 5.19 10.28 23.86 38.25 47.39 94.44 126.28 270.07 276.59 540.36 2.28 (1.45) 3.04 4.86 10.58) 0.37 10.77) 11.22) 127.44 256.71 235.96 434.46 1.88 3.91 3.50 6.40 1.87 3.85 3.45 6.31 133.27 132.12 132.73 133.93 2,627.79
Page 5
Jagsonpal Pharmaceuticals Limited Statement of Unaudited Standalone Assets and Liabilities as at 30 September 2026 (Rs. In Million) As at As at Sr. No. Particulars 30 September 31 March A 1 2 B 1 2 2026 2026 (Unaudited) (AuditE!_d) __ ASSETS Non-current assets Property, plant and equipment Right of use assets Goodwill Other intangible assets Financial assets Investments Other financial assets Income-tax assets (net) Other non-current assets Total non-current assets Current assets Inventories Financial assets Trade receivables Cash and cash equivalents Bank balances other than cash and equivalents above Other financial assets Other current assets Total current assets EQUITY AND LIABILITIES Equity Equity share capital Other equity Total equity Liabilities Non-current liabilities Financial liabilities Lease liabilities Provisions Deferred tax liabilities (net) Total non-current liabilities Current liabilities Financial liabilities Lease liabilities Trade payables Total outstanding dues of micro enterprises and small enterprises 5.60 60.26 96.93 652.65 199.99 251.66 0.66 27.55 1,295.30 194.38 269.91 190.93 949.01 0.65 54.06 1,658.94 132.12 2,305.89 2,438.01 59.11 9.51 49.65 118.27 15.42 33.92 Total outstanding dues of creditors other than micro enterprises and ---- 114_25 small enterprises Other financial liabilities Other current liabilities Provisions 9. 76 Current tax liabilities (net) '1;1::;,' 17.33 Total current liabi f • - 5.74 67.76 96.93 682.67 851.11 0.66 31.01 1,735.88 146.43 171.91 100.42 960.78 0.65 50.70 1,430.89 133.93 2,627.79 2,761.72 65.89 11.77 44.41 122.07 15.76 23.87 91.94 107.36 25.24 13.24 5.57
Page 6
Jagsonpal Pharmaceuticals Limited Statement of Unaudited Cash Flows (Rs. in Million) Half year ended 30 September 30 September Particulars - - - - ~- 2026 2025 A. Cash flows from operating activities Profit before tax Adjustments: Depreciation and amortisation expenses Exceptional items Interest income Finance costs Share based payment expense Excess provisions written back Provision for inventory obsolescence Operating cash flows before working capital changes Movement in working capital: (lncrease)/decrease in trade receivables (lncrease)/decrease in other current and non-current assets (lncrease)/decrease in inventories (lncrease)/decrease in other current and non-current financial assets lncrease/(decrease) in trade payables lncrease/(decrease) in other current liabilities and other financials liabilities lncrease/(decrease) in provisions Cash flows from operations Income-tax paid (net of refund) Net cash flows from operating activities (A) 8. Cash flows from investing activities Purchase of property, plant and equipment Cash paid for business acquisition (deferred consideration) Cash paid for purchase of subsidiary Investment in bank deposits Proceeds from maturity of bank deposits Interest received Net cash generated from/(used in) investing activities (B) C. Cash flows from financing activities Proceeds from issue of equity share capital (including securities premium) Buyback of equity shares (including related expenses) Finance costs paid Payment for principal portion of lease liabilities Payment for interest portion of lease liabilities Dividend paid Net cash used in financing activities (C) Net increase in cash and cash equivalents (A+B+C) Add: cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period Reconciliation of cash and cash equivalents as per the statement of cash flow Balance with banks in current accounts Cash on hand SIGNED FOR IDENTIFICATION PURPOSES -- -- (Unaudited) (Unaudited) 345.08 312.41 38.25 47.39 2.35 (50.01) (56.99) 5.02 5.19 35.38 31.26 (0.24) (0.37) 0.03 (0.22) 30.78 26.26 375.86 338.67 (97.76) (93.90) (1.35) (2.02) (47.98) (6.25) (0.24) (0.28) 32.36 32.36 66.71 31.10 4.26 1.16 331.86 300.84 (69.93) (54.09) 261.93 246.75 (0.60) (0.98) (5.35) (5.47) (207.84) (1,051.94) (713.79) 1,683.61 623.00 37.65 15.17 455.53 (82.07) 49.17 28.26 (401.14) (0.33) (0.87) (7.10) (5.39) (3.72) (4.32) (263.83) (166.58) (626.95) (148.90) 90.51 15.78 112.15 127.93 17 127.93 76 93 127.93 ,-. u~
Page 7
Jagsonpal Pharmaceuticals Limited Notes to the unaudited standalone financial results for the quarter and half year ended 30 September 2026 1. The unaudited standalone financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 2. The Company is primarily engaged in manufacturing and trading of pharmaceutical products (including active pharmaceutical ingredients) to its customers, which is being considered as a single reportable business segment by the chief operating decision maker. 3. During the previous year, effective 21 November 2025, the Government of India has consolidated multiple existing labour legislations into a unified framework comprising of f9ur Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020, collectively referred to as the 'New Labour Codes'. The enactment of these codes has resulted in changes to the computation of certain employee benefits. The Company has assessed the impact of these changes in accordance with Ind AS 19 - Employee Benefits and the guidance issued by the Institute of Chartered Accountants of India (ICAI). The resulting additional employee benefit expense of~ 20.79 million, being material and non-recurring, has been presented under "Exceptional Items" in the financial results for the year ended 31 March 2026. During the previous quarter, on 08 May 2026, the Central Government notified the Code of Wages (Central) Rules, 2026 and the Company is currently evaluating the consequential impact of these Rules. The Company continues to monitor developments pertaining to the Labour Codes and will provide appropriate accounting impact on the basis of such developments as needed. 4. During the quarter, under the Company's Employee Stock Option Plan 2022, the Company has granted 120,000 stock options to the eligible employees as determined by the Nomination and Remuneration Committee and has allotted 223,775 equity shares on exercise of vested stock options by eligible employees. 5. During the quarter, the Company has paid a final dividend of" 4 per equity share face value of " 2 each amounting to "! 263.83 millions for the year ended 31 March 2026 post shareholders' approval at the Annual General Meeting held on 18 September 2026. 6. During the quarter, the Company has acquired 85% equity stake in Aequitas Healthcare Private Limited for a consideration of "! 208 million with effect from 01 July 2026. The proposed acquisition marks Jagsonpal's strategic entry into the hospital segment and is aligned with the Company's long-term vision of strengthening its presence in India's growing healthcare ecosystem. Further, the Company has Involved various external experts to facilitate the said business combination for providing transaction related services amounting to~ 2.35 million, which has been disclosed as exceptional item. 7. During the quarter, the Company has entered into a Business Transfer Agreement ("BTA") with Group Pharmaceuticals Limited ("Seller") on 23 September 2026, for acquisition of the Wellness Portfolio of the Seller, on a going-concern basis by way of slump sale, subject to the terms and conditions contained in the BTA. While the Business Transfer Agreement was executed during the quarter, the completion of closing formalities, including fulfilment of the Conditions Precedent, were completed subsequently in October 2026 and therefore did not have any impact on the financial results of the Company for the quarter ended 30 September 2026. 8. The above standalone financial results for the quarter and half year ended 30 September 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 28 October 2026 and a limited review of the same has been carried out by the statutory auditors. Place : Gurugram Date : 28 October 2026 SIGNED FOR IDENTIFICATION PURPOSES \ Manish Gupta Managing Director
Page 8
Walker Chandiok &..Co LLP Walker Chandlok & Co LLP 21st Floor, DLF Square Jacaranda Marg, DLF Phase II Gurugram - 122 002 India T +91 124 4628099 F +91 124 4628001 Independent Auditor's Review Report on the Quarterly and Year to date Unaudited Consolidated Financial Results of Jagsonpal Pharmaceuticals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Jagsonpal Pharmaceuticals Limited 1. We have reviewed the accompanying statement of unaudited consolidated financial results of Jagsonpal Pharmaceuticals Limited ('the Holding Company') and its subsidiary (the Holding Company and its subsidiary together referred to as 'the Group'), (refer Annexure 1 for the subsidiary included in the Statement) for the quarter ended 30 September 2026 and year to date for the period 01 April 2026 to 30 September 2026 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). 2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable . .---..... k! f(l_'fr ccountants O'J'i< - ~ g • in Bengaluru, Chandigarh, Chennai, Guru gram, Hyderabad, Kechi, Kolkata, Mumbai, New Delhi, Naida and Pune Walker Chandiok & Co LLP is registered with limited liability with identification number MC-2085 and its registered office at L-41 Connaught Circus, New Delhi, 110001, India
Page 9
Walker Chandiok &.Co LLP Independent Auditor's Review Report on the Quarterly and Year to date Unaudited Consolidated Financial Results of Jagsonpal Pharmaceuticals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd) 4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review report of the other auditor referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 5. We did not review the interim financial information of the subsidiary included in the Statement whose financial information reflect total assets of~ 212.33 million as at 30 September 2026, and total revenues of~ 151.28 million, total net loss after tax of~ (0.03) million and total comprehensive loss of~ (0.01) million for the quarter and year-to-date period ended on 30 September 2026, and net cash outflows of~ (0.04) million for the year to date period ended on 30 September 2026, as considered in the Statement. These interim financial information have been reviewed by other auditor whose review report has been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the review report of such other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the report of the other auditor. For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/ N500013 Vinod Gupta Partner Membership No. 503690 UDIN: 26503690GXMTKX8951 Place: Gurugram Date: 28 October 2026
Page 10
Walker Chandiok &.Co LLP Independent Auditor's Review Report on the Quarterly and Year to date Unaudited Consolidated Financial Results of Jagsonpal Pharmaceuticals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd) Annexure 1 List of entities included in the Statement S. No. Name Relationship with the Holding Company 1 Jagsonpal Pharmaceuticals Limited Holding Company 2 Aequitas Healthcare Private Limited Subsidiary (with effect from 01 July 2026) Cha'118...., Accountants
Page 11
Jagsonpal Pharmaceuticals Limited Registered Office: lnnov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi - 110020 Corporate office: Plot No. 412-415,3rd Floor, Nimai Tower, Phase- IV, Udyog Vihar, Sector 18, Gurugram, Haryana-122015 CIN No:- L74899DL1978PLC009181 Phone:0124-4406710 Statement of Unaudited Consolidated Financial Results for the Quarter and Half Year ended 30 September 2026 Sr. No. 1 2 4 INCOME Revenue from operations Other income EXPENSES a) Cost of materials consumed b) Purchases of stock-in-trade Particulars c) Changes in inventories of finished goods, stock-in-trade and work-in-progress d) Employee benefits expense e) Finance costs f) Depreciation and amortisation expenses g) Other expenses 10 Other comprehensive income (OCI) i) a) Items that will not be reclassified to profit or loss b) Income tax relatin to items that will not be reclassified to rofit or loss 11 Total com rehensive income for the eriod 9+10 Profit for the period attributable to: Owners of the Holding Company Non-controllin interests Profit for the period Total comprehensive income for the period attributable to: Owners of the Holding Company Non-controlling interests Total com rehensive income for the eriod ___ 12_ _ Eamlngs per..equity_sbare (not_annualised for . ..the_quarte~/period)-. Basic (in Rs.) Diluted (in Rs.) 12 Paid-u e ul share capital (face value er share Rs. 2) SIGNED FOR IDENTIFICATION PURPOSES Quarter ended 30 September 2026 (Unaudited) (Refer note 8} 6 46.77 358.61 4.25 233.31 2.91 22.07 151.76 (2.71) 0.69 120.85 122.88 (0.01) 122.87 120.86 (0.01) 120.85 1.86 1.83 132.12 Half year ended 30 September 2026 (Unaudited) (Ref~r note 8} 1,786.03 50.84 95.43 619.11 (18.67) 461.09 5.45 43.49 287.63 (1.45) 0.37 253.68 254.77 (0.01) 254.76 253.69 (0.01 253.68 3.86 3.81 132.12
Page 12
Sr. No. A 1 2 B 1 2 Jagsonpal Pharmaceuticals Limited Statement of Unaudited Consolidated Assets and Liabilities as at 30 September 2026 ASSETS Non-current assets Property, plant and equipment Right-of-use assets Goodwill Other intangible assets Financial assets Other financial assets Deferred tax assets (net) Income tax assets (net) Other non-current assets Total non-current assets Current assets Inventories Financial assets Trade receivables Cash and cash equivalents Particulars Bank balances other than cash and cash equivalents Other financial assets Other current assets Total current assets EQUITY AND LIABILITIES Equity Equity share capital Other equity Equity attributable to owners of the Holding Company Non-controlling interests Total equity Liabilities Non-current liabilities Financial liabilities Lease liabilities Other financial liabilities Provisions Deferred tax liabilities (net) Total non-current liabilities Current liabilities Financial liabilities Borrowings Lease liabilities Trade payables Total outstanding dues of micro and small enterprises Total outstanding dues of creditors other than micro and small enterprises Other financial liabilit ies Other current liabilities Provisions ent tax liabilities (net) rrent liabilities N PURPOSES As at 30 September 2026 Unaudited ( Refer note 8) 5.86 67.88 183.12 793.38 244.71 4.10 1.19 27.55 1,327.79 265.89 374.96 191.32 961.31 0.66 60.73 132.12 2,274.04 2,406.16 36.69 2,442.85 65.18 36.30 12.25 84.36 198.09 8.96 18.02 43.57 224.73 156.65 51.81 20.65 17.33
Page 13
Jagsonpal Pharmaceuticals Limited Unaudited Consolidated Statement of Cash Flows for the Half Year Ended 30 September 2026 (Rs. in Million) Half year ended 30 September Particulars (Unaudited) • 2026 A. Cash flows from operating activities Profit before tax Adjustments: Depreciation and amortisation expenses Exceptional items Interest income Finance costs Share based payment expense Allowance for expected credit loss Excess provisions written back Provision for inventory obsolescence Operating cash flows before working capital changes Movement in working capital: (lncrease)/decrease in trade receivables (lncrease)/decrease in other current and non-current assets (lncrease)/decrease in inventories (lncrease)/decrease in other current and non-current financial assets lncrease/(decrease) in trade payables lncrease/(decrease) in other current liabilities and other financials liabilities lncrease/(decrease) in provisions Cash flows from operations Income-tax paid (net of refund) Net cash flows from operating activities (A) B. Cash flows from investing activities Purchase of property, plant and equipment Cash paid for business acquisition (deferred consideration) Cash paid for purchase of subsidiary Investment in bank deposits Proceeds from maturity of bank deposits Interest received Net cash flows from investing activities (B) C. Cash flows from financing activities Proceeds from issue of equity share capital (including securities premium) Movement in current borrowings (net) Buyback of equity shares (includ ing related expenses) Finance costs paid Payment for principal portion of lease liabilities Payment for interest portion of lease liabilities Dividend paid Net cash used in financing activities (C) Net Increase in cash and cash equivalents (A+B+C) Add: cash and cash equivalents at the beginning of the period Add: cash and cash equivalents of the subsidiary acquired during the period Cash and cash equivalents at the end of the period Reconciliation of cash and cash equivalents as per the statement of cash flow ~ 'r uivalents at the end of the period IDENTIFICATION PURPOSES (Refer note 8) 340.99 43.49 2.35 (50.19) 5.45 35.38 (0.17) (0.24) (1.55) 34.52 375.51 (110.18) (1.82) (34.24) (0.25) 24.96 70.65 4.35 328.98 (74.33) 254.65 (0.77) (5.35) (208.27) (1,051.94) 1,683.46 37.83 454.96 49.17 8.72 (401.14) (0.61) (8.01) (3.87) (263.83) (619.57) 90.04 100.85 0.43 191.32
Page 14
Jagsonpal Pharmaceuticals Limited Notes to the unaudited consolidated financial results for the quarter and half year ended 30 September 2026 1. The unaudited consolidated financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting {'Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 2. The Group comprises of following components: Name Relationship with Holding Company Aequitas Healthcare Private Limited Subsidiary (with effect from 1 July 2026) 3. The Group is primarily engaged in manufacturing and trading of pharmaceutical products (including active pharmaceutical ingredients) to its customers, which is being considered as a single reportable business segment by the chief operating decision maker. 4. During the quarter , under the Employee Stock Option Plan 2022, the Holding Company has granted 120,000 stock options to the eligible employees as determined by the Nomination and Remuneration Committee and has allotted 223,775 equity shares on exercise of vested stock options by eligible employees. 5. During the quarter, the Holding Company has paid a final dividend of Rs. 4 per equity share face value of Rs. 2 each amounting to Rs. 263.83 millions for the year ended 31 March 2026 post shareholders' approval at the Annual General Meeting held on 18 September 2026. 6. During the quarter, the Holding Company acquired an 85% equity stake in Aequitas Healthcare Private Limited for "208 million, effective 1 July 2026, marking its strategic entry into the hospital segment. The existing promoters/directors retain the remaining 15% stake. Transaction-related professional fees of "2.35 million have been recognised as an exceptional item. On acquisition, the Group recognised identifiable intangible assets at fair value, together with the related deferred tax liability, resulting in goodwill of "86 ml Ilion. Further, in accordance with the Shareholders' Agreement, a put liability of "29 million has been recognised in the consolidated financial results in respect of the obligation to acquire the residual 15% stake, in addition to the NCI recognised at the acquisition date. 7. During the quarter, the Holding Company has entered into a Business Transfer Agreement {"BTA") with Group Pharmaceuticals Limited ("Seller") on 23 September 2026, for acquisition of the Wellness Portfolio of the Seller, on a going-concern basis by way of slump sale, subject to the terms and conditions contained in the BTA. While the Business Transfer Agreement was executed during the quarter, the completion of closing formalities, including fulfilment of the Conditions Precedent, were completed subsequently in October 2026 and therefore, did not have any impact on the financial results of the Group for the quarter ended 30 September 2026. 8. During the quarter, pursuant to the acquisition of a controlling stake in Aequitas Healthcare Private Limited, the Holding Company has prepared consolidated financial results for the first time. Accordingly, comparative consolidated financial information for the corresponding quarter/previous periods is not applicable and has not been presented. 9. The above consolidated financial results for the quarter and half year ended 30 September 2026 have been reviewed by the Audit Committee and approved by the Board of Direct at their respective meetings held on 28 October 2026 and a limited. review of the same has been carried out by the statutory auditors. I Qg-c•"Dlok,\ * cy * n "' ~ !;; 91:-~ , ~,.;; Place : Gurug C Acco'0i Date : 28 October 2026 SIGNED FOR IDENTIFICATION PURPOSES Manish Gupta Managing Director